CN118496398A - Medical high polymer carrier and application thereof as skin protectant - Google Patents
Medical high polymer carrier and application thereof as skin protectant Download PDFInfo
- Publication number
- CN118496398A CN118496398A CN202410950183.7A CN202410950183A CN118496398A CN 118496398 A CN118496398 A CN 118496398A CN 202410950183 A CN202410950183 A CN 202410950183A CN 118496398 A CN118496398 A CN 118496398A
- Authority
- CN
- China
- Prior art keywords
- chitosan
- corosolic acid
- polymer carrier
- aqueous solution
- medical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0085—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the technical field of medical high polymer materials, in particular to a medical high polymer carrier and application thereof as a skin protective agent. The medical high polymer carrier is prepared by adopting the corosolic acid to chemically modify chitosan so as to prepare corosolic acid modified chitosan, and then the corosolic acid modified chitosan is used for processing hydrogel materials, and the corosolic acid modified chitosan hydrogel can be further used as a carrier for loading various medical active ingredients, so that the medical high polymer carrier is used as a skin protective agent, and has great application value.
Description
Technical Field
The invention relates to the technical field of medical high polymer materials, in particular to a medical high polymer carrier and application thereof as a skin protective agent.
Background
The dressing is a medical material for temporarily covering various wounds and wound surfaces, can be used for absorbing wound exudates, has the functions of stopping bleeding and promoting wound healing, and prevents the wounds from being affected by bacterial infection and other external factors. With the continuous development of modern medical technology, the types of medical hemostatic and wound healing promoting products are continuously updated, and at present, the developed novel wound dressing mainly comprises films, hydrocolloids, foams, electrostatic spinning products, polymer hydrogels and the like. The polymer hydrogel is mainly obtained by hydrophilic polymer crosslinking, has a better three-dimensional network structure, swells in water but is insoluble, and can be loaded with components with effects of promoting healing, sterilizing and the like while maintaining moisture, so that the polymer hydrogel has the characteristics of being soft in material, not adhered to a wound surface, resisting bacteria, effectively maintaining the moist environment of the wound surface, promoting the autolytic healing of the wound and the like, and meanwhile, the polymer hydrogel is used as a drug slow-release system, so that the drug release rate can be controlled, and the wound healing can be promoted, and the polymer hydrogel has wide research and application in the medical and skin care fields.
According to the classification of the preparation raw materials, the polymer hydrogels can be classified into natural polymer hydrogels and synthetic polymer hydrogels. The natural polymer hydrogel is nontoxic and harmless, has good biocompatibility and degradability, and has the characteristic of environmental friendliness, and can absorb part of wound seepage in the wound healing process to accommodate the formation of new tissues. At present, various natural polymers are applied to the preparation of hydrogel, and common polymers include alginate, chitosan, cellulose, hyaluronic acid, starch and the like, but when the natural polymers are used as wound dressing, the performance and the components of the natural polymers are optimized, so that the effects of diminishing inflammation, sterilizing and promoting healing in the use process are ensured. For example, the chinese patent of patent publication No. CN118078733a discloses a new recovery liquid gel preparation, and its preparation method and application, the composition of the new recovery liquid gel preparation includes 74.5-91.1 wt% of new recovery liquid, 13.6-16.6 wt% of polymer gel matrix and 1.9-2.3 wt% of cosolvent, the gel preparation uses polymer material chitosan and hyaluronic acid as gel matrix, uses acetic acid as cosolvent, and uses new recovery liquid as active substance, the new recovery liquid gel can effectively store medicine, and can achieve the effect of slowly releasing medicine, but the new recovery liquid gel preparation has the following drawbacks: although effective in promoting wound healing, the antibacterial properties, the biocompatibility of the matrix, etc. are still in need of improvement.
Disclosure of Invention
In order to solve the technical problems, the invention aims to provide a medical high-molecular polymer carrier and application thereof as a skin protective agent, wherein the medical high-molecular polymer carrier is prepared by modifying a natural high-molecular gel material, so that the medical high-molecular polymer carrier with better hydrophilic and antibacterial effects can be further used for loading medical active ingredients and is used as the skin protective agent, and the medical high-molecular polymer carrier has great application value.
In order to achieve the technical effects, the invention adopts the following technical scheme:
In a first aspect, the present invention provides a medical polymer carrier, which includes a modified chitosan matrix, the modified chitosan matrix has a porous structure, and a medical active ingredient can be loaded in the porous structure, preferably, the medical active ingredient has at least any function of antibacterial and promoting wound healing.
In a second aspect, the present invention also provides a method for preparing the medical high polymer carrier, which comprises the following steps:
s1: preparing chitosan aqueous solution;
s2: modifying chitosan by adopting corosolic acid to obtain corosolic acid modified chitosan;
S3: the corosolic acid modified chitosan is used as a raw material to prepare a medical high polymer carrier.
Further, the step S1 is: dissolving chitosan in an acidic aqueous solution with pH of 4-6, and stirring to completely dissolve the chitosan to obtain a chitosan aqueous solution;
preferably, the acidic aqueous solution is hydrochloric acid aqueous solution or acetic acid aqueous solution;
preferably, the chitosan water contains 2-6 wt% of chitosan.
Further, the step S2 is: dissolving corosolic acid in absolute ethyl alcohol at a specific reaction temperature, adding a coupling agent into the absolute ethyl alcohol after the corosolic acid is completely dissolved to obtain a modified solution, mixing the modified solution with the chitosan aqueous solution, reacting for 10-30 hours under a stirring condition, dialyzing to remove unreacted micromolecular substances after the reaction is finished, and freeze-drying to obtain corosolic acid modified chitosan;
preferably, the molar ratio of the corosolic acid to the chitosan is 1:10-15;
preferably, the reaction temperature is 20-40 ℃;
Preferably, the coupling agent is any one or a mixture of EDC and NHS.
Further, the step S3 is: dissolving the corosolic acid modified chitosan in a dispersion solvent to prepare a medical high molecular polymer carrier;
Preferably, the dispersion solvent is any one of deionized water, a buffer solution and an acidic aqueous solution.
The invention also provides an application of the medical high polymer carrier in the aspect of serving as a skin protective agent, in particular to a skin protective agent for nursing wounds on the surface of skin.
Further, the skin protective agent is a wound care hydrogel, and the wound care hydrogel further comprises an antibacterial active ingredient.
Preferably, the antibacterial active ingredient is any one or a mixture of silybin and eucommia ulmoides extract.
Preferably, the antibacterial active ingredients comprise silybin and eucommia ulmoides extract, and the total addition amount of the silybin and the eucommia ulmoides extract is 1-4 wt% of the medical high-molecular polymer carrier.
Preferably, the application comprises the steps of:
S01: preparing corosolic acid modified chitosan;
S02: dissolving the corosolic acid modified chitosan in a dispersion solvent, and then adding antibacterial active ingredients into the dispersion solvent to uniformly disperse the antibacterial active ingredients; preferably, the dispersion solvent is any one of deionized water, a buffer solution, and an acidic aqueous solution.
Compared with the prior art, the invention has the beneficial effects that:
The invention provides a medical high polymer carrier and application thereof as a skin protective agent, wherein the medical high polymer carrier is prepared by adopting corosolic acid to chemically modify chitosan, and then the corosolic acid modified chitosan is used for processing hydrogel materials, and the corosolic acid modified chitosan hydrogel can be further used as a carrier for loading various medical active ingredients, so that the medical high polymer carrier is used as the skin protective agent, and has great application value.
The preparation method of the corosolic acid modified chitosan is simple, and the prepared hydrogel material is hydrophilic and breathable, and is beneficial to slow release of medical active ingredients loaded on the hydrogel carrier, so that the acting time of the corosolic acid modified chitosan is prolonged, and the corosolic acid modified chitosan has a good application value in the aspect of being used as a skin protective agent.
Detailed Description
The following examples are only for more clearly illustrating the technical aspects of the present invention, and thus are merely examples, and are not intended to limit the scope of the present invention. Any equivalent modifications and substitutions of the embodiments described below will be apparent to those skilled in the art, and are intended to be within the scope of the present invention. Accordingly, equivalent changes and modifications are intended to be included within the scope of the present invention without departing from the spirit and scope thereof. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. All reagents or equipment were commercially available as conventional products without the manufacturer's attention.
Numerous specific details are set forth in the following description in order to provide a better understanding of the invention. It will be understood by those skilled in the art that the present invention may be practiced without some of these specific details. In other embodiments, methods, means, apparatus and steps well known to those skilled in the art have not been described in detail in order to not obscure the present invention.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Unless otherwise indicated, all units used in this specification are units of international standard, and all numerical values and ranges appearing in the present invention are understood to include unavoidable errors in industrial production.
Example 1
Chitosan is a cationic polysaccharide existing in nature, and the formed polycation can interact with a negatively charged bacterial membrane to influence the metabolic activity of bacteria, so that broad-spectrum antibacterial activity is generated.
Corosolic acid is a pentacyclic triterpene natural compound with the following structural formula:
The corosolic acid is mainly derived from loquat leaves, crape myrtle leaves, actinidia septicum, sea buckthorn leaves and the like, and researches show that the corosolic acid has various pharmacological activities of reducing blood sugar, resisting tumors, resisting inflammation, resisting oxidation, resisting bacteria and the like, has good development potential and wide application prospect (Zhang Jianxiu, liu Huizhe, apocynum, and the like, the pharmacological effect research of the corosolic acid is progressed [ J ]. International journal of pharmaceutical research, 2019, 46 (01): 22-26. DOI: 10.13220/j.cnki.jipr.2019.01.004.).
The preparation method of the medical high-molecular polymer carrier provided by the embodiment comprises the following steps: the chitosan is modified by adopting corosolic acid to prepare corosolic acid modified chitosan, and the corosolic acid modified chitosan is dissolved in a dispersion solvent, wherein the dispersion solvent is any one of deionized water, a buffer solution and an acidic aqueous solution, and is preferably PBS buffer solution.
Specifically, the medical high polymer carrier provided in this embodiment is prepared according to the following method:
s1: preparation of an aqueous chitosan solution:
dissolving chitosan (0.01 mmol) in an acetic acid aqueous solution (100 g) with the pH of 5-5.5, and stirring to completely dissolve the chitosan to obtain a chitosan aqueous solution;
S2: the method for modifying chitosan by adopting corosolic acid comprises the following steps:
Dissolving corosolic acid (0.02 mol) in absolute ethyl alcohol (30 ml) at 25-30 ℃, and adding a coupling agent (comprising 0.02mol of each of 1-ethyl- (3-dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS)) into the solution after the corosolic acid is completely dissolved to obtain a modified solution;
Mixing the prepared modified solution with the chitosan aqueous solution prepared in the step S1, reacting 24 h (30 ℃) under stirring, dialyzing 24 h after the reaction is finished to remove unreacted micromolecular substances, and freeze-drying to obtain corosolic acid modified chitosan powder;
s3: the corosolic acid modified chitosan powder is taken as a raw material to prepare a medical high polymer carrier, specifically, the corosolic acid modified chitosan (4 wt%) powder prepared in the step S2 is dissolved in PBS solution to prepare corosolic acid modified chitosan hydrogel, and the experimental sample I is obtained.
Example 2
On the basis of embodiment 1, this embodiment provides a preparation method of a medical high polymer carrier, specifically including the steps of:
s1: preparation of an aqueous chitosan solution:
Dissolving chitosan (0.011 mmol) in an acetic acid aqueous solution (100 g) with the pH of 5-5.5, and stirring to completely dissolve the chitosan to obtain a chitosan aqueous solution;
S2: the method for modifying chitosan by adopting corosolic acid comprises the following steps:
Dissolving corosolic acid (0.025 mol) in absolute ethanol (35 ml) at 28 ℃, and adding a coupling agent (comprising 1-ethyl- (3-dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS) respectively 0.025 mol) into the solution after the corosolic acid is completely dissolved to obtain a modified solution;
mixing the prepared modified solution with the chitosan aqueous solution prepared in the step S1, reacting under stirring for 30 h, dialyzing for 30 h after the reaction is finished to remove unreacted micromolecular substances, and freeze-drying to obtain corosolic acid modified chitosan powder;
S3: the corosolic acid modified chitosan is used as a raw material to prepare a medical high polymer carrier, specifically, the corosolic acid modified chitosan (4 wt%) prepared in the step S2 is dissolved in PBS solution to prepare corosolic acid modified chitosan hydrogel, and the corosolic acid modified chitosan hydrogel is recorded as an experimental sample II.
Example 3
This example is a comparative example to example 1, which uses gallic acid (0.02 mol) instead of corosolic acid in example 1 to prepare a gallic acid modified chitosan hydrogel, and the preparation method is described as control sample I with reference to example 1.
Example 4
This example is a comparative example to example 1, which uses cinnamic acid (0.02 mol) in place of corosolic acid in example 1 to prepare a cinnamic acid-modified chitosan hydrogel, and was recorded as control sample II with reference to example 1.
Test example 1
The antibacterial activity of each modified chitosan hydrogel was tested by using a plurality of groups of modified chitosan hydrogels (4 wt%) prepared in the foregoing examples 1-4 as test objects, using a PBS solution as a negative control, using oxford cup method (coating with a bacterial solution concentration of 1 x 10 8 CFU/ml, and repeating the steps for three times at 37 ℃ for 24 hours), and using the diameter of the antibacterial zone to react with the antibacterial activity of each modified chitosan hydrogel, and experimental strains including propionibacterium acnes, staphylococcus aureus and escherichia coli were shown in table 1:
Table 1 results of antibacterial Activity test of modified Chitosan hydrogels (4 wt%)
According to the experimental results, the PBS solution has no inhibition effect on three bacteria, the chemical modification shows obvious inhibition effect on the chitosan hydrogel on the three bacteria, and the chitosan hydrogel prepared by adopting the corosolic acid modification provided by the invention has more obvious antibacterial effect on Propionibacterium acnes, staphylococcus aureus and escherichia coli compared with chitosan hydrogel modified by gallic acid and cinnamic acid, especially for the growth of Propionibacterium acnes, the corosolic acid modified chitosan hydrogel has better performance, and can be used as a skin care agent for acne.
In addition, the water absorption performance of each group of modified chitosan hydrogels prepared in the foregoing examples 1 to 4 was tested using the groups of modified chitosan hydrogels (4 wt%) as test objects, and the test method was: modified chitosan hydrogel (4 wt%) was prepared, then placed in PBS buffer at 37℃and pH 7.4, and the modified chitosan hydrogel was taken out at 0.5h, 1h, 2h, 3h, 6h, 8h and 12h, respectively, weighed, and the swelling degree was calculated as follows:
Wherein W t is the mass of the modified chitosan hydrogel after water absorption under the test time, and W 0 is the mass of the modified chitosan water at the initial time.
The experimental results are shown in table 2:
TABLE 2 results of swelling degree test of modified Chitosan hydrogels
The experimental results show that the swelling degree of the chitosan hydrogel prepared by modifying the corosolic acid is higher and is at most 1557.02%, and the swelling degree of the chitosan hydrogel prepared by modifying the gallic acid and the cinnamic acid under the same conditions is at most 1102.6% and 687.10%, respectively. Meanwhile, the swelling speed of the chitosan hydrogel prepared by the corosolic acid modification is faster, the swelling balance can be achieved in about 3 hours, and the swelling speed of the cinnamic acid modified chitosan gel is faster, but the swelling degree of the cinnamic acid modified chitosan gel is low, so that the corosolic acid modified chitosan hydrogel can show better water absorption when the corosolic acid modified chitosan hydrogel is used for nursing skin wound surfaces, and is beneficial to quickly absorbing wound surface tissue fluid.
Example 5
In this example, based on the experimental result of this experimental example 1, the present inventors further tested that the corosolic acid modified chitosan hydrogel was used for loading an antibacterial active ingredient to prepare a hydrogel for wound care, and specifically, the preparation method of the hydrogel for wound care was as follows:
S01: the corosolic acid modified chitosan was prepared as in example 1;
S02: dissolving corosolic acid modified chitosan (4 g) in PBS buffer solution (50 g) to obtain solution I, dissolving silybin (0.8 g, purchased from Shanxi kepler biotechnology Co., ltd.) and eucommia ulmoides extract (0.8 g, purchased from Sipuno major biotechnology Co., ltd.) in PBS buffer solution (44 g) to obtain solution II, mixing the solution II and the solution I, stirring to fully fuse the solution II and the solution I, and obtaining the wound care hydrogel which is recorded as experiment group I.
Example 6
Referring to the foregoing example 5, a hydrogel for wound care was prepared and recorded as a control group II, which is different from the control group I in step S02, specifically, in this example, step S02 is:
s02: dissolving the corosolic acid modified chitosan (4 g) in PBS buffer solution (50 g) to obtain solution I;
silybin (1.6 g, available from kepler biotechnology Co., ltd. In Shanxi) was dissolved in PBS buffer solution (44 g) to obtain solution II, and the solution II was mixed with solution I and stirred to allow the two to be sufficiently fused to obtain hydrogel for wound care, which was recorded as control group I.
Example 7
Referring to the foregoing example 5, a hydrogel for wound care was prepared and recorded as a control group II, which is different from the control group I in step S02, specifically, in this example, step S02 is:
s02: dissolving the corosolic acid modified chitosan (4 g) in PBS buffer solution (50 g) to obtain solution I;
Dissolving Eucommiae cortex extract (1.6 g, purchased from Siam Biotechnology Co., ltd.) in PBS buffer solution (44 g) to obtain solution II, mixing the solution II and the solution I, stirring to make the two sufficiently fused to obtain hydrogel for wound care, and recording as control group II.
Test example 2
Based on the foregoing examples 5-7, the antibacterial performance of the experimental group I, the control group I and the control group II prepared in this experimental example was further tested to observe the antibacterial effect difference of the hydrogel (containing antibacterial active ingredient) for wound care of each group, the experiment was performed by oxford cup method (using bacterial liquid concentration 1×10 8 CFU/ml for coating, incubation condition is 37 ℃ for 24 hours), and the three times were repeated to record the diameter of the inhibition zone, and the experimental results are shown in table 3:
table 3 results of experiments on antibacterial effect of hydrogel for wound care of each group
The experimental results show that the silybin and the eucommia ulmoides extract are taken as antibacterial active ingredients together and are loaded on the chitosan hydrogel carrier, and the silybin and the eucommia ulmoides extract can show obvious synergistic effect in inhibiting the growth of propionibacterium acnes, staphylococcus aureus and escherichia coli. Meanwhile, the corosolic acid chitosan hydrogel carrier is also beneficial to helping the slow release of antibacterial active ingredients, improves the wound repair effect, and has great application value in the aspect of serving as a wound skin protective agent.
The above embodiments are only for illustrating the technical solution of the present invention and not for limiting the same, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications and equivalents may be made thereto without departing from the spirit and scope of the technical solution of the present invention, which is intended to be covered by the scope of the claims of the present invention. The technology, shape, and construction parts of the present invention, which are not described in detail, are known in the art.
Claims (8)
1. The preparation method of the medical high polymer carrier is characterized by comprising the following steps:
s1: preparing chitosan aqueous solution;
s2: modifying chitosan by adopting corosolic acid to obtain corosolic acid modified chitosan;
S3: the corosolic acid modified chitosan is used as a raw material to prepare a medical high polymer carrier.
2. The method for preparing a medical polymer carrier according to claim 1, wherein the step S1 is: dissolving chitosan in an acidic aqueous solution with pH of 4-6, and stirring to completely dissolve the chitosan to obtain a chitosan aqueous solution; the acidic aqueous solution is hydrochloric acid aqueous solution or acetic acid aqueous solution; the chitosan aqueous solution contains 2-6 wt% of chitosan.
3. The method for preparing a medical polymer carrier according to claim 1, wherein the step S2 is: under a specific reaction temperature, dissolving corosolic acid in absolute ethyl alcohol, adding a coupling agent into the absolute ethyl alcohol after the corosolic acid is completely dissolved to obtain a modified solution, mixing the modified solution with the chitosan aqueous solution, reacting for 10-30 hours under a stirring condition, dialyzing to remove unreacted micromolecular substances after the reaction is finished, and freeze-drying to obtain the corosolic acid modified chitosan.
4. The method for preparing a medical polymer carrier according to claim 1, wherein the step S3 is: dissolving the corosolic acid modified chitosan in a dispersion solvent to prepare a medical high molecular polymer carrier; the dispersion solvent is any one of deionized water, buffer solution and acidic aqueous solution.
5. Use of a medical polymer carrier prepared by the preparation method according to any one of claims 1 to 4 as a skin protectant.
6. The use according to claim 5, wherein: the skin protective agent is a hydrogel for wound care, and the hydrogel for wound care also comprises an antibacterial active ingredient.
7. The use according to claim 6, wherein: the antibacterial active ingredient is any one or mixture of silybin and eucommia ulmoides extract.
8. The use according to claim 6, wherein: the antibacterial active ingredients comprise silybin and eucommia ulmoides extract, and the total addition amount of the silybin and the eucommia ulmoides extract is 1-4 wt% of the medical high polymer carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410950183.7A CN118496398B (en) | 2024-07-16 | 2024-07-16 | Medical high polymer carrier and application thereof as skin protectant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410950183.7A CN118496398B (en) | 2024-07-16 | 2024-07-16 | Medical high polymer carrier and application thereof as skin protectant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN118496398A true CN118496398A (en) | 2024-08-16 |
| CN118496398B CN118496398B (en) | 2024-10-11 |
Family
ID=92229528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410950183.7A Active CN118496398B (en) | 2024-07-16 | 2024-07-16 | Medical high polymer carrier and application thereof as skin protectant |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118496398B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119174836A (en) * | 2024-11-26 | 2024-12-24 | 哈尔滨运美达生物科技有限公司 | Preparation method of antioxidant and antibacterial chitosan composite material |
| CN120000839A (en) * | 2025-04-22 | 2025-05-16 | 南昌沪士达医疗科技有限公司 | Porous hemostatic sponge with high liquid absorption rate and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100316739A1 (en) * | 2008-01-18 | 2010-12-16 | Ariel Shaul Hasson Nisis | Chitosan gel for dermatological use, production method therefor and use of same |
| KR20110045377A (en) * | 2009-10-26 | 2011-05-04 | 세종대학교산학협력단 | Complex functional chitosan colloid and preparation method thereof |
| CN103705939A (en) * | 2013-12-30 | 2014-04-09 | 中国药科大学 | Preparation of amphiphilic ursolic acid-polysaccharide coupled substance and application thereof in treating tumors |
| CN107375940A (en) * | 2017-07-18 | 2017-11-24 | 福州大学 | Nano medication with adhesion factor ICAM 1 for target spot prepares and its application |
| CN113318234A (en) * | 2021-06-11 | 2021-08-31 | 盐城师范学院 | Arginine and ursolic acid modified chitosan nano drug delivery carrier and preparation method and application thereof |
| CN113402630A (en) * | 2021-06-11 | 2021-09-17 | 盐城师范学院 | Chitosan derivative drug delivery carrier and preparation method and application thereof |
-
2024
- 2024-07-16 CN CN202410950183.7A patent/CN118496398B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100316739A1 (en) * | 2008-01-18 | 2010-12-16 | Ariel Shaul Hasson Nisis | Chitosan gel for dermatological use, production method therefor and use of same |
| KR20110045377A (en) * | 2009-10-26 | 2011-05-04 | 세종대학교산학협력단 | Complex functional chitosan colloid and preparation method thereof |
| CN103705939A (en) * | 2013-12-30 | 2014-04-09 | 中国药科大学 | Preparation of amphiphilic ursolic acid-polysaccharide coupled substance and application thereof in treating tumors |
| CN107375940A (en) * | 2017-07-18 | 2017-11-24 | 福州大学 | Nano medication with adhesion factor ICAM 1 for target spot prepares and its application |
| CN113318234A (en) * | 2021-06-11 | 2021-08-31 | 盐城师范学院 | Arginine and ursolic acid modified chitosan nano drug delivery carrier and preparation method and application thereof |
| CN113402630A (en) * | 2021-06-11 | 2021-09-17 | 盐城师范学院 | Chitosan derivative drug delivery carrier and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 汪多仁: "《绿色医药化学品》", vol. 1, 31 July 2008, 科学技术文献出版社, pages: 145 - 146 * |
| 顾其胜等: "《壳聚糖基海洋生物医用材料》", vol. 1, 31 January 2020, 上海科学技术出版社, pages: 18 - 19 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119174836A (en) * | 2024-11-26 | 2024-12-24 | 哈尔滨运美达生物科技有限公司 | Preparation method of antioxidant and antibacterial chitosan composite material |
| CN120000839A (en) * | 2025-04-22 | 2025-05-16 | 南昌沪士达医疗科技有限公司 | Porous hemostatic sponge with high liquid absorption rate and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118496398B (en) | 2024-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110448722B (en) | An injectable temperature-sensitive composite antibacterial hydrogel material containing tannic acid and its preparation and application | |
| CN111154149A (en) | A kind of hydrogel and its preparation method and dressing | |
| Zhao et al. | In situ cross-linked polysaccharide hydrogel as extracellular matrix mimics for antibiotics delivery | |
| CN105778126B (en) | Genipin cross-linked biogel and preparation method and application thereof | |
| CN110314242B (en) | Preparation method and application of controlled-release antibiotic composite hydrogel | |
| Zhang et al. | Synthesis, characterization, and evaluation of poly (aminoethyl) modified chitosan and its hydrogel used as antibacterial wound dressing | |
| HK1246216B (en) | Antimicrobial composition | |
| HK1246216A (en) | Antimicrobial composition | |
| Huang et al. | Preparation of novel stable microbicidal hydrogel films as potential wound dressing | |
| CN118496398B (en) | Medical high polymer carrier and application thereof as skin protectant | |
| CN112480434B (en) | A kind of copper ion antibacterial hydrogel and preparation method and application | |
| CN113214507B (en) | Preparation method of antibacterial glycopeptide hydrogel | |
| Zhao et al. | Engineering pH responsive carboxyethyl chitosan and oxidized pectin-based hydrogels with self-healing, biodegradable and antibacterial properties for wound healing | |
| CN116350840B (en) | An antibacterial, antioxidative, self-adhesive multifunctional composite hydrogel dressing and preparation method thereof | |
| Li et al. | Injectable, rapid self-healing, antioxidant and antibacterial nanocellulose-tannin hydrogels formed via metal-ligand coordination for drug delivery and wound dressing | |
| Zhang et al. | Tunicate-mimetic antibacterial hydrogel based on metal ion crosslinking and chitosan functionalization for wound healing | |
| CN103265732A (en) | Chitosan-ethylcellulose blending membrane and preparation method thereof, and blending gel | |
| CN115944774A (en) | Rosmarinic acid-chitosan-polyvinyl alcohol hydrogel dressing and preparation method and application thereof | |
| CN113509591A (en) | Antibacterial cationic injectable hydrogel dressing and preparation method thereof | |
| Ding et al. | Antibacterial polyurethane foams with quaternized-chitosan as a chain extender for nasal packing and hemostasis | |
| CN112472867A (en) | Antibacterial medical hydrogel dressing and preparation method thereof | |
| CN114479124B (en) | Self-healing hydrogel, preparation method and application thereof | |
| EP3241569B1 (en) | Antimicrobial composition | |
| CN111150887B (en) | Antibacterial composite bracket CS/SF/CMs-CIP for promoting healing of seawater-soaked wound and preparation method thereof | |
| EP4185638A1 (en) | Blended polyvinyl alcohol drug delivery systems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |